{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:08:48Z","timestamp":1794661728716,"version":"4.9.1"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.pharmthera.2023.108431","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T20:53:47Z","timestamp":1683147227000},"page":"108431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["The antidepressant actions of ketamine and its enantiomers"],"prefix":"10.1016","volume":"246","author":[{"given":"Jenessa N.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioline D.","family":"Henter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2023.108431_bb0005","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/s41386-020-0668-1","article-title":"(2R, 6R)-Hydroxynorketamine (HNK) plasma level predicts poor antidepressant response: is this the end of the HNK pipeline?","volume":"45","author":"Abdallah","year":"2020","journal-title":"Neuropsychopharmacology."},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108431_bb0010","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41386-022-01266-9","article-title":"Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial","volume":"47","author":"Abdallah","year":"2022","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jad.2019.11.028","article-title":"Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression","volume":"263","author":"Acevedo-Diaz","year":"2020","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109313","article-title":"Roles of the monoaminergic system in the antidepressant effects of ketamine and its metabolites","volume":"223","author":"Ago","year":"2023","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.25122\/jml-2020-0116","article-title":"The effect of ketamine on preventing postpartum depression","volume":"14","author":"Alipoor","year":"2021","journal-title":"Journal of Medicine and Life"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0030","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0035","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyad016","article-title":"Sex and oestrous cycle are not mediators of S-ketamine\u2019s rapid-antidepressant behavioural effects in a genetic rat model of depression","author":"Arjmand","year":"2023","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0040","author":"Atai Life Sciences"},{"issue":"7354","key":"10.1016\/j.pharmthera.2023.108431_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0050","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0055","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1038\/s41467-020-20190-4","article-title":"The role of dissociation in ketamine\u2019s antidepressant effects","volume":"11","author":"Ballard","year":"2020","journal-title":"Nature Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108431_bb0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HRP.0000000000000330","article-title":"Ketamine in the treatment of obsessive-compulsive disorder: a systematic review","volume":"30","author":"Bandeira","year":"2022","journal-title":"Harvard Review of Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0065","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00131746-200409000-00003","article-title":"Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment","volume":"10","author":"Belzer","year":"2004","journal-title":"Journal of Psychiatric Practice"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108431_bb0070","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/phar.2664","article-title":"Response to intravenous racemic ketamine after switch from intranasal (S)-ketamine on symptoms of treatment-resistant depression and post-traumatic stress disorder in veterans: a retrospective case series","volume":"42","author":"Bentley","year":"2022","journal-title":"Pharmacotherapy."},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108431_bb0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biological Psychiatry"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108431_bb0080","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Molecular Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108431_bb0085","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0090","first-page":"875","article-title":"Ketamine hypertension and the renin-angiotensin system","volume":"5","author":"Broughton Pipkin","year":"1983","journal-title":"Clinical and Experimental Hypertension. Part A"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0095","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jpsychires.2021.09.057","article-title":"The resilient phenotype elicited by ketamine against inflammatory stressors-induced depressive-like behavior is associated with NLRP3-driven signaling pathway","volume":"144","author":"Camargo","year":"2021","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0100","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.116.235838","article-title":"Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters","volume":"359","author":"Can","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108431_bb0105","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"The American Journal of Psychiatry"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108431_bb0110","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40263-021-00846-5","article-title":"Prevention and management of common adverse effects of ketamine and esketamine in patients with mood disorders","volume":"35","author":"Ceban","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108431_bb0120","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41386-020-0714-z","article-title":"Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine","volume":"45","author":"Chen","year":"2020","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0125","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41380-022-01447-4","article-title":"Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al","volume":"27","author":"Chen","year":"2022","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0130","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/NDT.S391096","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray plus a newly initiated oral antidepressant in adult patients with treatment-resistant depression: a randomized, double-blind, multicenter, active-controlled study conducted in China and USA","volume":"19","author":"Chen","year":"2023","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0135","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jad.2019.11.086","article-title":"Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study","volume":"264","author":"Correia-Melo","year":"2020","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2022.100505","article-title":"A randomized pilot study of the prophylactic effect of ketamine on laboratory-induced stress in healthy adults","volume":"22","author":"Costi","year":"2023","journal-title":"Neurobiology of Stress."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0145","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108431_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ph16010031","article-title":"Impact of repeated doses of subcutaneous esketamine on acute dissociative symptoms in treatment-resistant depression","volume":"16","author":"Del Sant","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0155","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3109\/00498254.2012.685777","article-title":"Stereoselective and regiospecific hydroxylation of ketamine and norketamine","volume":"42","author":"Desta","year":"2012","journal-title":"Xenobiotica."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109335","article-title":"Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine","volume":"224","author":"Deyama","year":"2023","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0165","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Classic papers revisited: taming the ketamine tiger by Edward F. Domino","volume":"113","author":"Domino","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(97)01116-3","article-title":"Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord","volume":"333","author":"Ebert","year":"1997","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0175","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0024-3205(01)01287-5","article-title":"Tissue uptake of ketamine and norketamine enantiomers in the rat: indirect evidence for extrahepatic metabolic inversion","volume":"69","author":"Edwards","year":"2001","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.833259","article-title":"Ketamine as a prophylactic resilience-enhancing agent","volume":"13","author":"Evers","year":"2022","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder","volume":"178","author":"Feder","year":"2021","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0190","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0195","series-title":"Ketamine for treatment-resistant deprssion: The first decade of progress","first-page":"13","article-title":"The basic and clinical pharmacology of ketamine","author":"Fourcade","year":"2016"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0200","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00213-019-05346-5","article-title":"MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling","volume":"237","author":"Fujita","year":"2020","journal-title":"Psychopharmacology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173954","article-title":"Dextran sulfate sodium-induced inflammation and colitis in mice are ameliorated by (R)-ketamine, but not (S)-ketamine: a role of TrkB signaling","volume":"897","author":"Fujita","year":"2021","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0210","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1213\/00000539-199901000-00033","article-title":"The effects of ketamine and propofol on neuronal nicotinic acetylcholine receptors and P2X purinoceptors in PC12 cells","volume":"88","author":"Furuya","year":"1999","journal-title":"Anesthesia and Analgesia"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0215","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.3390\/ijms23094555","article-title":"A new player in depression: miRNAs as modulators of altered synaptic plasticity","volume":"23","author":"Gao","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0220","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/bja\/75.4.506","article-title":"Pharmacokinetics of ketamine enantiomers","volume":"75","author":"Geisslinger","year":"1995","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0225","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0378-4347(91)80350-L","article-title":"Stereoselective high-performance liquid chromatographic determination of the enantiomers of ketamine and norketamine in plasma","volume":"568","author":"Geisslinger","year":"1991","journal-title":"Journal of Chromatography"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0230","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0269881119874457","article-title":"Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study","volume":"34","author":"Glue","year":"2020","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12871-022-01588-7","article-title":"S-ketamine as an adjuvant in patient-controlled intravenous analgesia for preventing postpartum depression: a randomized controlled trial","volume":"22","author":"Han","year":"2022","journal-title":"BMC Anesthesiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108431_bb0240","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/02698811211064922","article-title":"Sex-dependent metabolism of ketamine and (2R,6R)-hydroxynorketamine in mice and humans","volume":"36","author":"Highland","year":"2022","journal-title":"Journal of Psychopharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108431_bb0245","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/dmd.30.7.853","article-title":"Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes","volume":"30","author":"Hijazi","year":"2002","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109171","article-title":"Ketamine; history and role in anesthetic pharmacology","volume":"216","author":"Hirota","year":"2022","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0255","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0773.1995.tb01041.x","article-title":"Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors","volume":"77","author":"Hustveit","year":"1995","journal-title":"Pharmacology & Toxicology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0260","first-page":"431","article-title":"Stereoselective pharmacokinetics of ketamine: R(\u2212)-ketamine inhibits the elimination of S(+)-ketamine","volume":"70","author":"Ihmsen","year":"2001","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103518","article-title":"Inflammation, stress and depression: an exploration of ketamine\u2019s therapeutic profile","volume":"28","author":"Johnston","year":"2023","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109422","article-title":"Ketamine and serotonergic psychedelics: an update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment","volume":"226","author":"Johnston","year":"2023","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0275","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fpsyt.2018.00277","article-title":"Efficacy of ketamine in the treatment of substance use disorders: a systematic review","volume":"9","author":"Jones","year":"2018","journal-title":"Frontiers in Psychiatry"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108431_bb0280","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/mp.2017.109","article-title":"Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder","volume":"23","author":"Kadriu","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0285","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.bja.2020.06.067","article-title":"Pharmacokinetics of ketamine and its major metabolites norketamine, hydroxynorketamine, and dehydronorketamine: a model-based analysis","volume":"2020","author":"Kamp","year":"2020","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0290","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/ALN.0000000000003577","article-title":"Ketamine pharmacokinetics: a systematic review of the literature, meta-analysis, and population analysis","volume":"133","author":"Kamp","year":"2020","journal-title":"Anesthesiology."},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108431_bb0295","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychological Medicine"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0300","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1176\/jnp.15.1.27","article-title":"Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT","volume":"15","author":"Krystal","year":"2003","journal-title":"The Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0305","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jpsychires.2022.04.035","article-title":"The abuse liability of ketamine: a scoping review of preclinical and clinical studies","volume":"151","author":"Le","year":"2022","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0310","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","volume":"271","author":"Leal","year":"2021","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0315","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jad.2023.02.151","article-title":"Arketamine as adjunctive therapy for treatment-resistant depression: a placebo-controlled pilot study","volume":"330","author":"Leal","year":"2023","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109513","article-title":"A synaptic locus for TrkB signaling underlying ketamine rapid antidepressant action","volume":"36","author":"Lin","year":"2021","journal-title":"Cell Reports"},{"issue":"14","key":"10.1016\/j.pharmthera.2023.108431_bb0325","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.neuron.2022.05.001","article-title":"Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2","volume":"110","author":"Lopez","year":"2022","journal-title":"Neuron."},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108431_bb0330","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1073\/pnas.1816071116","article-title":"Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function","volume":"116","author":"Lumsden","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0335","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.psychres.2019.03.026","article-title":"Prophylactic use of ketamine reduces postpartum depression in Chinese women undergoing cesarean section","volume":"279","author":"Ma","year":"2019","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109250","article-title":"A role of microRNA-149 in the prefrontal cortex for prophylactic actions of (R)-ketamine in inflammation model","volume":"219","author":"Ma","year":"2022","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0345","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41398-022-02192-6","article-title":"A key role of miR-132-5p in the prefrontal cortex for persistent prophylactic actions of (R)-ketamine in mice","volume":"12","author":"Ma","year":"2022","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-022-01803-6","article-title":"Nuclear factor of activated T cells 4 in the prefrontal cortex is required for prophylactic actions of (R)-ketamine","volume":"12","author":"Ma","year":"2022","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0355","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/s41467-017-01709-8","article-title":"TrkB dependent adult hippocampal progenitor differentiation mediates sustained ketamine antidepressant response","volume":"8","author":"Ma","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0360","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019","volume":"277","author":"Marcantoni","year":"2020","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0365","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.112238","article-title":"Prophylactic (R,S)-ketamine selectively protects against inflammatory stressors","volume":"378","author":"Mastrodonato","year":"2020","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0375","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ijnp\/pyac020","article-title":"Prophylactic (R, S)-ketamine is effective against stress-induced behaviors in adolescent but not aged mice","volume":"25","author":"Mastrodonato","year":"2022","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0380","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","article-title":"The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis","volume":"276","author":"McIntyre","year":"2020","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0385","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S2215-0366(20)30255-8","article-title":"Neuroinflammation in psychiatric disorders: PET imaging and promising new targets","volume":"7","author":"Meyer","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0390","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neuropharm.2015.07.028","article-title":"Two cellular hypotheses explaining the initiation of ketamine\u2019s antidepressant actions: direct inhibition and disinhibition","volume":"100","author":"Miller","year":"2016","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0395","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/EJA.0000000000000638","article-title":"History of anaesthesia: the ketamine story - past, present and future","volume":"34","author":"Mion","year":"2017","journal-title":"European Journal of Anaesthesiology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0400","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/cns.12099","article-title":"Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings)","volume":"19","author":"Mion","year":"2013","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0405","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0006-3223(01)01362-2","article-title":"Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders","volume":"51","author":"Moghaddam","year":"2002","journal-title":"Biological Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108431_bb0410","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0415","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00213-021-05767-1","article-title":"Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment","volume":"238","author":"Ng","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0420","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamapsychiatry.2022.1074","article-title":"Evaluation of the trajectory of depression severity with ketamine and esketamine treatment in a clinical setting","volume":"79","author":"Nikayin","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0425","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00213-022-06105-9","article-title":"The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits","volume":"239","author":"Nogo","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0430","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fnmol.2014.00094","article-title":"Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade","volume":"7","author":"Nosyreva","year":"2014","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0435","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1523\/JNEUROSCI.4998-12.2013","article-title":"Acute suppression of spontaneous neurotransmission drives synaptic potentiation","volume":"33","author":"Nosyreva","year":"2013","journal-title":"The Journal of Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108431_bb0440","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0022-3565(25)38235-2","article-title":"Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid","volume":"265","author":"Nowak","year":"1993","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0445","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0022-3565(25)11430-4","article-title":"Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors","volume":"260","author":"Oye","year":"1992","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0450","first-page":"59","article-title":"Ketamine. Continuing education in anaesthesia","volume":"7","author":"Pai","year":"2007","journal-title":"Critical Care, and Pain"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0455","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.173011","article-title":"Distinct cognitive and discriminative stimulus effects of ketamine enantiomers in rats","volume":"197","author":"Popik","year":"2020","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108431_bb0465","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"The American Journal of Psychiatry"},{"issue":"51","key":"10.1016\/j.pharmthera.2023.108431_bb0470","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1016\/j.chroma.2010.06.028","article-title":"Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro","volume":"1217","author":"Portmann","year":"2010","journal-title":"Journal of Chromatography. A"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0475","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.44514","article-title":"Effect of intraoperative esketamine infusion on postoperative sleep disturbance after gynecological laparoscopy: a randomized clinical trial","volume":"5","author":"Qiu","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0480","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00406-020-01208-w","article-title":"Rapid-acting and long-lasting antidepressant-like action of (R)-ketamine in Nrf2 knock-out mice: a role of TrkB signaling","volume":"271","author":"Qu","year":"2021","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0485","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/ph15020125","article-title":"Combined administration of (R)-ketamine and the mGlu2\/3 receptor antagonist LY341495 induces rapid and sustained effects in the CUMS model of depression via a TrkB\/BDNF-dependent mechanism","volume":"15","author":"Rafa\u0142o-Uli\u0144ska","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113633","article-title":"The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL\/6J mice","volume":"418","author":"Rafa\u0142o-Uli\u0144ska","year":"2022","journal-title":"Behavioural Brain Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108431_bb0495","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/ALN.0000000000001392","article-title":"Role of cytochrome P4502B6 polymorphisms in ketamine metabolism and clearance","volume":"125","author":"Rao","year":"2016","journal-title":"Anesthesiology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0500","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/ijms23031294","article-title":"A systematic review of circulatory microRNAs in major depressive disorder: potential biomarkers for disease prognosis","volume":"23","author":"Rasheed","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0505","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neubiorev.2016.03.004","article-title":"Assessing anhedonia in depression: potentials and pitfalls","volume":"65","author":"Rizvi","year":"2016","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0510","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/da.22536","article-title":"A review of ketamine abuse and diversion","volume":"33","author":"Sassano-Higgins","year":"2016","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0515","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF01066320","article-title":"Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man","volume":"15","author":"Sch\u00fcttler","year":"1987","journal-title":"Journal of Pharmacokinetics and Biopharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0520","article-title":"Bone density and depressive disorder: a meta-analysis","volume":"6","author":"Schweiger","year":"2016","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173523","article-title":"Differentially regulated targets in the fast-acting antidepressant effect of (R)-ketamine: a systems biology approach","volume":"223","author":"Scotton","year":"2023","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0530","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/bja\/44.11.1200","article-title":"Ketamine anesthesia in patients with intracranial pathology","volume":"44","author":"Shapiro","year":"1972","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0535","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41398-020-00897-0","article-title":"A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression","volume":"10","author":"Shiroma","year":"2020","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0540","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/ALN.0b013e3181b437b1","article-title":"S(+)-ketamine effect on experimental pain and cardiac output: a population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers","volume":"111","author":"Sigtermans","year":"2009","journal-title":"Anesthesiology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0545","doi-asserted-by":"crossref","first-page":"22m14548","DOI":"10.4088\/JCP.22m14548","article-title":"Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study","volume":"84","author":"Singh","year":"2023","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0550","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0555","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0028-3908(81)90015-0","article-title":"Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines","volume":"20","author":"Smith","year":"1981","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0560","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature22084","article-title":"Effects of a ketamine metabolite on synaptic NMDAR function","volume":"546","author":"Suzuki","year":"2017","journal-title":"Nature."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0565","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12888-021-03538-y","article-title":"The basic and clinical pharmacology of ketamine","volume":"21","author":"Takahashi","year":"2021","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172839","article-title":"Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: role of BDNF-TrkB signaling","volume":"188","author":"Tan","year":"2020","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108431_bb0575","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neubiorev.2010.06.006","article-title":"Reconsidering anhedonia in depression: lessons from translational neuroscience","volume":"35","author":"Treadway","year":"2011","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0580","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/cpdd.993","article-title":"Pharmacokinetic modeling of ketamine enantiomers and their metabolites after administration of prolonged-release ketamine with emphasis on 2, 6-hydroxynorketamines","volume":"11","author":"Weiss","year":"2022","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0585","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211056743","article-title":"Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders","volume":"11","author":"Whittaker","year":"2021","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"13","key":"10.1016\/j.pharmthera.2023.108431_bb0590","first-page":"E3007","article-title":"Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy","volume":"115","author":"Widman","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0595","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0600","doi-asserted-by":"crossref","first-page":"21m14318","DOI":"10.4088\/JCP.21m14318","article-title":"Longitudinal course of adverse events with esketamine nasal spray: A post hoc analysis of pooled data from phase 3 trials in patients with treatment-resistant depression","volume":"83","author":"Williamson","year":"2022","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0605","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/0004867419883341","article-title":"Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials","volume":"54","author":"Witt","year":"2020","journal-title":"The Australian and New Zealand Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0610","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00404-017-4334-8","article-title":"Single bolus low-dose of ketamine does not prevent postpartum depression: a randomized, double-blind, placebo-controlled, prospective clinical trial","volume":"295","author":"Xu","year":"2017","journal-title":"Archives of Gynecology and Obstetrics"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0615","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0301-0082(99)00007-6","article-title":"Subunit- and site-specific pharmacology of the NMDA receptor channel","volume":"59","author":"Yamakura","year":"1999","journal-title":"Progress in Neurobiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108431_bb0620","first-page":"887","article-title":"Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes","volume":"29","author":"Yanagihara","year":"2001","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0625","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R, 6R)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0630","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin\u2013independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0635","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0640","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0645","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41380-021-01377-7","article-title":"Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine","volume":"27","author":"Yao","year":"2022","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172876","article-title":"(S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression","volume":"191","author":"Yokoyama","year":"2020","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0655","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1523\/JNEUROSCI.1316-22.2022","article-title":"NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine","volume":"43","author":"Zanos","year":"2023","journal-title":"The Journal of Neuroscience"},{"issue":"7604","key":"10.1016\/j.pharmthera.2023.108431_bb0660","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0665","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacological Reviews"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108431_bb0670","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biological Psychiatry"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108431_bb0675","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0680","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0014-2999(92)90248-3","article-title":"Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons","volume":"213","author":"Zeilhofer","year":"1992","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0685","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00213-021-05889-6","article-title":"(R)-ketamine attenuates LPS-induced endotoxin-derived delirium through inhibition of neuroinflammation","volume":"238","author":"Zhang","year":"2021","journal-title":"Psychopharmacology."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0690","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R (\u2212)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0695","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/ijnp\/pyx100","article-title":"Role of inflammatory bone markers in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model","volume":"21","author":"Zhang","year":"2018","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0700","first-page":"10","article-title":"Essential role of microglial transforming growth factor-\u03b21 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-\u03b21. Transl","author":"Zhang","year":"2020","journal-title":"Psychiatry."},{"key":"10.1016\/j.pharmthera.2023.108431_bb0705","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.bbr.2017.05.064","article-title":"Behavioral, inflammatory and neurochemical disturbances in LPS and UCMS-induced mouse models of depression","volume":"364","author":"Zhao","year":"2019","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2023.108431_bb0710","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10571-021-01180-6","article-title":"S-ketamine exerts antidepressant effects by regulating Rac1 GTPase mediated synaptic plasticity in the hippocampus of stressed rats","volume":"43","author":"Zhu","year":"2023","journal-title":"Cellular and Molecular Neurobiology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823000955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823000955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:31:29Z","timestamp":1759012289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823000955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":142,"alternative-id":["S0163725823000955"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108431","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The antidepressant actions of ketamine and its enantiomers","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108431"}}